Edwards Lifesciences vs West Pharmaceutical Services

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (88 vs 92)
Edwards Lifesciences logo

Edwards Lifesciences

LeaderHealthcare Tech

Enterprise

Irvine CA structural heart devices (NYSE: EW) at $5.44B 2024 revenue; 60% TAVR global share, EVOQUE tricuspid +88% in Q4, Critical Care sold to BD for $4.2B, JenaValve acquisition expanding to aortic regurgitation.

AI VisibilityBeta
Overall Score
A88
Category Rank
#76 of 290
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
88
Perplexity
81
Gemini
94

About

Edwards Lifesciences Corporation is an Irvine, California-based structural heart disease and hemodynamic monitoring technology company — publicly traded on the New York Stock Exchange (NYSE: EW) as an S&P 500 Healthcare component — designing, developing, and manufacturing devices for heart valve replacement, transcatheter heart valve therapy, and cardiac critical care through approximately 15,800 employees in 100+ countries. In fiscal year 2024, Edwards reported total revenue of $5.44 billion (+8.6% year-over-year), driven by its dominant Transcatheter Aortic Valve Replacement (TAVR) franchise commanding approximately 60% global market share and 70%+ US market share. The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment demonstrated exceptional growth, with Q4 TMTT revenue reaching $105 million (+88% year-over-year), as the EVOQUE tricuspid replacement system gained commercial momentum. In 2024, Edwards executed a major strategic transformation: divesting its Critical Care segment (hemodynamic monitoring) to Becton Dickinson for $4.2 billion — using the proceeds to fund two acquisitions: JenaValve Technology ($1.2B combined, expanding TAVR to high-risk patients with aortic regurgitation) and Endotronix. The company concentrates its entire focus on structural heart disease therapies.

Full profile
West Pharmaceutical Services logo

West Pharmaceutical Services

LeaderHealthcare Tech

Pharmaceutical Packaging

West Pharmaceutical Services (WST) reported ~$3.0B revenue in FY2024. Designs packaging components and delivery systems for injectable drugs — critical for vaccine and biologic drug manufacturing. HQ: Exton, PA.

AI VisibilityBeta
Overall Score
A92
Category Rank
#1 of 1
AI Consensus
71%
Trend
up
Per Platform
ChatGPT
92
Perplexity
88
Gemini
98

About

West Pharmaceutical Services, Inc. is the global leader in packaging components and delivery systems for injectable medications, designing and manufacturing the stoppers, closures, caps, and drug delivery systems that seal vials, syringes, and cartridges containing vaccines, biologics, and injectable drugs. Every major pharmaceutical company and biologic manufacturer relies on West's containment solutions — the small rubber stopper sealing an mRNA vaccine vial or insulin cartridge is almost certainly a West product.

Full profile

AI Visibility Head-to-Head

88
Overall Score
92
#76
Category Rank
#1
68
AI Consensus
71
stable
Trend
up
88
ChatGPT
92
81
Perplexity
88
94
Gemini
98
82
Claude
96
88
Grok
87

Key Details

Category
Enterprise
Pharmaceutical Packaging
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only West Pharmaceutical Services
Pharmaceutical Packaging

Integrations

Both integrate with
Edwards Lifesciences is classified as company. West Pharmaceutical Services is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.